Community Practice Considerations for Integrating CAR-T Therapy for Relapsed/Refractory Multiple Myeloma: The Role of Multidisciplinary Care

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
54-year-old male relapses after autologous HSCT followed by carfilzomib, lenalidomide, and dexamethasone. What do you offer next?
The most common acute toxicities of BCMA immunotherapies are:
The challenge with using tocilizumab to manage CRS is:
Powered by QuestionPro